| payload |
{"created_at":"2026-04-22T03:03:32.063 {"created_at":"2026-04-22T03:03:32.063787+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:f16f164939953436","evidence_event_ids":["evt_3cb6a53c2b30"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-045629.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-045629.txt","company":"Sagimet Biosciences Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-045629.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_562f1ce7d5fa5a5b","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-045629.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:30:09.680584+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-045629.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-045629.txt","source_event_id":"evt_3cb6a53c2b30","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"10d9ea3df1ca6164","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["2026-04-20","2026-04-21","2026-04-22"],"entities":[{"asset_class":"equity","name":"Sagimet Biosciences Inc.","relevance":"high","symbol":"SGMT","type":"issuer"},{"asset_class":"person","name":"Eduardo Martins, M.D., D.Phil.","relevance":"high","symbol":"","type":"person"},{"asset_class":"person","name":"Andreas Grauer, M.D.","relevance":"high","symbol":"","type":"person"},{"asset_class":"equity","name":"Omeros Corporation","relevance":"medium","symbol":"OMER","type":"company"},{"asset_class":"company","name":"Federation Bio","relevance":"medium","symbol":"","type":"company"},{"asset_class":"company","name":"Corcept Therapeutics Incorporated","relevance":"medium","symbol":"","type":"company"},{"asset_class":"company","name":"Amgen, Inc.","relevance":"medium","symbol":"","type":"company"},{"asset_class":"company","name":"Procter & Gamble Pharmaceuticals","relevance":"low","symbol":"","type":"company"},{"asset_class":"institution","name":"University of Heidelberg Medical School","relevance":"low","symbol":"","type":"institution"}],"event_type":"other","information_gaps":["The filing\u2019s SEC accession number and the specific 8-K filing timestamp are not provided in the cleaned text (only the filing date is given in the structured context).","No financial guidance, earnings figures, or quantitative business impact are disclosed in the provided text.","The prior known state referenced by the signal (what was previously known before this delta) is not included, so the exact change vs prior state cannot be determined beyond the events stated in this filing."],"key_facts":["Form 8-K filed for Sagimet Biosciences Inc. with date of earliest event reported as April 20, 2026.","Item 5.02: Eduardo Martins, M.D., D.Phil. provided notice of retirement from his role as Chief Medical Officer effective April 20, 2026.","Item 5.02: Eduardo Martins will continue to support the Company as an external scientific advisor.","Item 8.01: The Company announced the appointment of Andreas Grauer, M.D. as Chief Medical Officer effective April 20, 2026.","Andreas Grauer most recently served as Chief Medical Officer at Omeros Corporation (NASDAQ: OMER) from October 2023 to April 2026.","Andreas Grauer previously served as Chief Medical Officer at Federation Bio (October 2021 to July 2023) and at Corcept Therapeutics Incorporated (March 2019 to August 2021).","Andreas Grauer held various positions at Amgen, Inc. (December 2008 to December 2018), including Vice President Global Development.","Andreas Grauer began his career at Procter & Gamble Pharmaceuticals (1999 to November 2008).","Andreas Grauer continues to serve as an Associate Professor of Medicine at the University of Heidelberg Medical School, Germany, where he received his M.D. and completed clinical training in internal medicine and endocrinology."],"numeric_claims":[],"primary_claim":"On April 20, 2026, Sagimet Biosciences reported Eduardo Martins\u2019 retirement as Chief Medical Officer and the appointment of Andreas Grauer, M.D. as Chief Medical Officer, both effective April 20, 2026.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Sagimet Biosciences Inc. filed a Form 8-K reporting (i) the retirement of its Chief Medical Officer, Eduardo Martins, effective April 20, 2026, and (ii) the appointment of Andreas Grauer, M.D. as Chief Medical Officer effective April 20, 2026.","topics":["Form 8-K","Chief Medical Officer transition","director/officer retirement","chief medical officer appointment","biographical background"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Sagimet Biosciences Inc. \u00b7 Filed 20260421","ticker":"SGMT","tickers":["SGMT"],"title":"SGMT filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-045629.txt"}}... |